Cargando…

Acylation of the antimicrobial peptide CAMEL for cancer gene therapy

Obtaining ideal gene delivery vectors is still a major goal in cancer gene therapy. CAMEL, a short hybrid antimicrobial peptide, can kill cancer cells by membrane lysis. In this study, we constructed a series of non-viral vectors by attaching fatty acids with different chain lengths to the N-terminu...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Jingjing, Ma, Panpan, Huang, Sujie, Wang, Juanli, Xie, Huan, Jia, Bo, Zhang, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216477/
https://www.ncbi.nlm.nih.gov/pubmed/32611259
http://dx.doi.org/10.1080/10717544.2020.1787556
_version_ 1783710427100741632
author Song, Jingjing
Ma, Panpan
Huang, Sujie
Wang, Juanli
Xie, Huan
Jia, Bo
Zhang, Wei
author_facet Song, Jingjing
Ma, Panpan
Huang, Sujie
Wang, Juanli
Xie, Huan
Jia, Bo
Zhang, Wei
author_sort Song, Jingjing
collection PubMed
description Obtaining ideal gene delivery vectors is still a major goal in cancer gene therapy. CAMEL, a short hybrid antimicrobial peptide, can kill cancer cells by membrane lysis. In this study, we constructed a series of non-viral vectors by attaching fatty acids with different chain lengths to the N-terminus of CAMEL. Our results showed that the cellular uptake and transfection efficiency of acyl-CAMEL started to significantly increase from a chain length of 12 carbons. C18-CAMEL was screened for gene delivery because it had the highest transfection efficiency. Surprisingly, C18-CAMEL/plasmid complexes displayed strong endosomal escape activity after entering cells via endocytosis. Importantly, C18-CAMEL could deliver p53 plasmids to cancer cells and significantly inhibited cell proliferation by the expression of p53. In addition, the C18-CAMEL/p53 plasmid complexes and the MDM2 inhibitor nutlin-3a showed significantly synergistic anticancer activity against MCF-7 cells expressing wild-type p53. Conclusively, our study demonstrated that conjugation of stearic acid to antimicrobial peptides is a simple and successful approach for constructing efficient and economical non-viral vectors for cancer gene therapy.
format Online
Article
Text
id pubmed-8216477
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-82164772021-07-06 Acylation of the antimicrobial peptide CAMEL for cancer gene therapy Song, Jingjing Ma, Panpan Huang, Sujie Wang, Juanli Xie, Huan Jia, Bo Zhang, Wei Drug Deliv Research Article Obtaining ideal gene delivery vectors is still a major goal in cancer gene therapy. CAMEL, a short hybrid antimicrobial peptide, can kill cancer cells by membrane lysis. In this study, we constructed a series of non-viral vectors by attaching fatty acids with different chain lengths to the N-terminus of CAMEL. Our results showed that the cellular uptake and transfection efficiency of acyl-CAMEL started to significantly increase from a chain length of 12 carbons. C18-CAMEL was screened for gene delivery because it had the highest transfection efficiency. Surprisingly, C18-CAMEL/plasmid complexes displayed strong endosomal escape activity after entering cells via endocytosis. Importantly, C18-CAMEL could deliver p53 plasmids to cancer cells and significantly inhibited cell proliferation by the expression of p53. In addition, the C18-CAMEL/p53 plasmid complexes and the MDM2 inhibitor nutlin-3a showed significantly synergistic anticancer activity against MCF-7 cells expressing wild-type p53. Conclusively, our study demonstrated that conjugation of stearic acid to antimicrobial peptides is a simple and successful approach for constructing efficient and economical non-viral vectors for cancer gene therapy. Taylor & Francis 2020-07-02 /pmc/articles/PMC8216477/ /pubmed/32611259 http://dx.doi.org/10.1080/10717544.2020.1787556 Text en © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Song, Jingjing
Ma, Panpan
Huang, Sujie
Wang, Juanli
Xie, Huan
Jia, Bo
Zhang, Wei
Acylation of the antimicrobial peptide CAMEL for cancer gene therapy
title Acylation of the antimicrobial peptide CAMEL for cancer gene therapy
title_full Acylation of the antimicrobial peptide CAMEL for cancer gene therapy
title_fullStr Acylation of the antimicrobial peptide CAMEL for cancer gene therapy
title_full_unstemmed Acylation of the antimicrobial peptide CAMEL for cancer gene therapy
title_short Acylation of the antimicrobial peptide CAMEL for cancer gene therapy
title_sort acylation of the antimicrobial peptide camel for cancer gene therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8216477/
https://www.ncbi.nlm.nih.gov/pubmed/32611259
http://dx.doi.org/10.1080/10717544.2020.1787556
work_keys_str_mv AT songjingjing acylationoftheantimicrobialpeptidecamelforcancergenetherapy
AT mapanpan acylationoftheantimicrobialpeptidecamelforcancergenetherapy
AT huangsujie acylationoftheantimicrobialpeptidecamelforcancergenetherapy
AT wangjuanli acylationoftheantimicrobialpeptidecamelforcancergenetherapy
AT xiehuan acylationoftheantimicrobialpeptidecamelforcancergenetherapy
AT jiabo acylationoftheantimicrobialpeptidecamelforcancergenetherapy
AT zhangwei acylationoftheantimicrobialpeptidecamelforcancergenetherapy